<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01147289</url>
  </required_header>
  <id_info>
    <org_study_id>EF 102</org_study_id>
    <nct_id>NCT01147289</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic Pain</brief_title>
  <acronym>Dextra</acronym>
  <official_title>A Phase III, Randomized, Multicenter, Open Label Clinical Trial: Efficacy and Safety of the Injectable Association of Dexamethasone, Dipyrone, and Hydrocobalamin in Lumbar Sciatic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III, randomized, multicenter, open label clinical trial to evaluate efficacy and
      safety of the injectable association of dexamethasone, dipyrone, and hydroxocobalamin in
      lumbar sciatic pain. The study will enroll 140 patients in each arm (280 total).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>The efficacy analysis will be at the per protocol population, with the VAS measure after three treatment dosages. The VAS scale consists on a straight line of 100 mm in which the patient marks, at any point through the straight line, the point he/she considers to describe the pain level he/she feels. After the patient marks the straight line, classifying his/her pain, it is measured with a millimeter-graded standard rule, the distance between the mark and the extremity &quot;No pain&quot; at the scale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Lumbar Sciatic Pain</condition>
  <arm_group>
    <arm_group_label>dexalgen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose for 3 days, at least</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose for at least 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextralgen</intervention_name>
    <description>Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.</description>
    <arm_group_label>dexalgen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <description>Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.</description>
    <arm_group_label>Meloxicam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign the study informed consent form;

          -  To be diagnosed with moderate to severe lumbar sciatic pain (defined as limiting the
             work activities or the ordinary tasks performance or at the investigator's discretion)
             within the last 3 days;

          -  Aged 18 to 75 years old;

          -  To be able to meet the study procedures

        Exclusion Criteria:

        o-Diagnosed with chronic rheumatologic diseases, except recurrent lumbar sciatic pain;

          -  Patients with one of the following conditions, as per the investigator's criteria:

          -  Severe renal failure under hemodialysis, severe liver failure, uncontrolled severe
             heart failure;

          -  Severe injuries on gastrointestinal tract;

          -  Other severe comorbidities;

          -  Patients taking acetylsalicylic acid or any anti-clotting;

          -  Female patients who are pregnant, lactating, willing to get pregnant or not willing to
             use an appropriate contraceptive method during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Gorios, Phd./MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sociedade Beneficente São Camilo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paulo Guilherme Oliveira e Silva, Phd/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Marcelina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luciana Teixeira Pinto, Phd/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Pesquisa Clínica e Medicina Avançada (IMA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Raj Eis, Phd/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEDOES</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Alexandre Mendonça, Phd/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Pesquisa Clínica de Campinas (IPECC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia Maria Silva, Phd/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina ABC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CEDOES</name>
      <address>
        <city>Vitoria</city>
        <state>Espirito Santo</state>
        <zip>29055-450</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente São Camilo</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>05022-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto De Pesquisa Clínica De Campinas IPECC</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13073-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clínica e Medicina Avançada Ltda IMA</name>
      <address>
        <city>São paulo</city>
        <zip>05437-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina</name>
      <address>
        <city>São Paulo</city>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina ABC</name>
      <address>
        <city>São Paulo</city>
        <zip>0960-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2010</study_first_submitted>
  <study_first_submitted_qc>June 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <name_title>Estela Bellini Pannuti</name_title>
    <organization>Eurofarma Laboratorios Ltda</organization>
  </responsible_party>
  <keyword>lumbar sciatic pain</keyword>
  <keyword>moderate to severe lumbar sciatic pain within the last three days</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dipyrone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

